Abstract:International Journal of Stroke, Ahead of Print. Background:Approximately one in four stroke patients suffer from recurrent vascular events, underlying the necessity to improve secondary stroke prevention strategies. Immune mechanisms are causally associated with coronary atherosclerosis. However, stroke is a heterogeneous disease and the relative contribution of inflammation across stroke mechanisms is not well understood. The optimal design of future randomized control trials (RCTs) of anti-inflammatory therapies to prevent recurrence after stroke must be informed by a clear understanding of the prognostic role of inflammation according to stroke subtype and individual patient factors.Aim:In this narrative review, we discuss (1) inflammatory pathways in the etiology of ischemic stroke subtypes; (2) the evidence on inflammatory markers and vascular recurrence after stroke; and (3) review RCT evidence of anti-inflammatory agents for vascular prevention.Summary of review:Experimental work, genetic epidemiological data, and plaque-imaging studies all implicate inflammation in atherosclerotic stroke. However, emerging evidence also suggests that inflammatory mechanisms are also important in other stroke mechanisms. Advanced neuroimaging techniques support the role of neuroinflammation in blood–brain barrier dysfunction in cerebral small vessel disease (cSVD). Systemic inflammatory processes also promote atrial cardiopathy, incident and recurrent atrial fibrillation (AF). Although several inflammatory markers have been associated with recurrence after stroke, interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) are presently the most promising markers to identify patients at increased vascular risk. Several RCTs have shown that anti-inflammatory therapies reduce vascular risk, including stroke, in coronary artery disease (CAD). Some, but not all of these trials, selected patients on the basis of elevated hsCRP. Although unproven after stroke, targeting inflammation to reduce recurrence is a compelling strategy and several RCTs are ongoing.Conclusion:Evidence points toward the importance of inflammation across multiple stroke etiologies and potential benefit of anti-inflammatory targets in secondary stroke prevention. Taking the heterogeneous stroke etiologies into account, the use of serum biomarkers could be useful to identify patients with residual inflammatory risk and perform biomarker-led patient selection for future RCTs.

Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Inflammatory biomarkers of ischemic stroke

Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke

Neuroinflammation in Acute Ischemic and Hemorrhagic Stroke

Inflammatory mechanisms in ischemic stroke: therapeutic approaches

Inflammatory biomarkers in blood of patients with acute brain ischemia

Role of DAMPs and of Leukocytes Infiltration in Ischemic Stroke: Insights from Animal Models and Translation to the Human Disease

Inflammation biomarkers in the intracranial blood are associated with outcome in patients with ischemic stroke

Acute ischemic stroke biomarkers: a new era with diagnostic promise?

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review

Targeting inflammation to reduce recurrent stroke

Diagnostic and Prognostic Blood Biomarkers in Transient Ischemic Attack and Minor Ischemic Stroke: An Up-To-Date Narrative Review

New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications

Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke

Effect of Inflammation on the Process of Stroke Rehabilitation and Poststroke Depression

Advances in neuroprotective therapy for acute ischemic stroke

Dynamic inflammatory changes of the neurovascular units after ischemic stroke.

Immune-inflammatory, Oxidative Stress and Biochemical Biomarkers Predict Short-Term Acute Ischemic Stroke Death.

Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches